PharmExec

FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer

FDA’s conditional approval of Jemperli (dostarlimab-gxly) rests on a single-arm phase 2 trial, with independent-review data ...
PharmExec

Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion

Merck KGaA, Darmstadt, Germany, agrees to acquire Silence Therapeutics for roughly $1.3 billion, gaining a siRNA asset, ...
PharmExecOpinion

Is Participation in MFN Voluntary?

Pharmaceutical Executive spoke with John Stanford, executive director at Incubate, about the current status of MFN and how ...
PharmExec

Hansoh Pharma Enters $15 Billion Collaboration and License Agreement with Roche

Hansoh Pharmaceutical Group Co., Ltd. announced it has entered into a strategic collaboration and license agreement with Roche covering a broad portfolio of antibody-drug conjugat ...